• Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

    Source: Nasdaq GlobeNewswire / 07 Nov 2022 07:00:01   America/Chicago

    NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day, taking place November 14th-15th, 2022.

    Guggenheim 4th Annual Immunology and Neurology Day fireside chat details:
      
    Date:Monday, November 14th, 2022
      
    Time:3:55 pm Eastern Time
      
    Webcast:The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com.

    About Immunovant, Inc. 
    Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. For additional information on the Company, please visit www.immunovant.com. 

    Contact:
    Chau Cheng, PhD, MBA
    Vice President, Investor Relations
    Immunovant, Inc.
    info@immunovant.com 


Share on,